Halozyme Therapeutics (HALO) Earnings Date, Estimates & Call Transcripts

Halozyme Therapeutics logo
$95.94 -0.57 (-0.59%)
As of 11:14 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Halozyme Therapeutics Earnings Summary

Halozyme Therapeutics announced Q3 2026 earnings on November 5, 2026, reporting an EPS of $2.39, which topped the consensus estimate of $2.30 by $0.09. Quarterly revenue rose 39.1% year-over-year to $492.97 million, above analysts' expectations of $491.63 million. With a trailing EPS of $3.93 and a P/E Ratio of 24.65, Halozyme Therapeutics' earnings are expected to grow 17.51% next year, from $8.34 to $9.80 per share.

Latest Q3
Earnings Date
Nov. 5Estimated
Consensus EPS
(Nov. 5)
$2.30
Actual EPS
(Nov. 5)
$2.39 Beat By $0.09
Actual Revenue
(Nov. 5)
$492.97M

Q3 2026 Earnings Resources

Get Halozyme Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Halozyme Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

HALO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

HALO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Halozyme Therapeutics Analyst EPS Estimates & Company Guidance

Low, high and average are individual analyst estimates we track. Guidance columns are the company's own outlook, and the revenue estimate was recorded when that guidance was issued.

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany EPS GuidanceCompany Revenue GuidanceRevenue Estimate at Guidance
Q1 20261$1.42$1.42$1.42
Q2 20261$1.72$1.72$1.72
Q3 20261$2.06$2.06$2.06
Q4 20261$2.53$2.53$2.53
FY 20264$7.73$7.73$7.73
Q1 20271$1.78$1.78$1.78
Q2 20271$2.04$2.04$2.04
Q3 20271$2.16$2.16$2.16
Q4 20271$3.03$3.03$3.03
FY 20274$9.01$9.01$9.01
Q1 20281$2.05$2.05$2.05
Q2 20281$2.71$2.71$2.71

Halozyme Therapeutics Earnings History by Quarter

Report Date
0 Results
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026$2.30$2.39+$0.09$2.01$491.63M$492.97M
8/6/2026Q2 2026$1.79$2.28+$0.49$1.90$402.28M$481.00M
5/11/2026Q1 2026$1.54$1.60+$0.06$1.22$358.60M$376.71M
2/17/2026Q4 2025$1.92-$0.24 -$2.16-$1.20$446.13M$451.77M
11/3/2025Q3 2025$1.63$1.72+$0.09$1.43$339.18M$354.26M
8/5/2025Q2 2025$1.23$1.54+$0.31$1.33$282.66M$325.72M
5/6/2025Q1 2025$0.98$1.11+$0.13$0.93$231.21M$264.86M
2/18/2025Q4 2024$1.17$1.19+$0.02$1.06$285.74M$298.01M

Halozyme Therapeutics Earnings - Frequently Asked Questions

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earning data on Thursday, November 5, 2026. Learn more on HALO's earnings history.

In the previous quarter, Halozyme Therapeutics (NASDAQ:HALO) reported $2.39 earnings per share (EPS) to beat the analysts' consensus estimate of $2.30 by $0.09. Learn more on analysts' earnings estimate vs. HALO's actual earnings.

The conference call for Halozyme Therapeutics' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Halozyme Therapeutics' latest earnings report can be read online.
Read Transcript

Halozyme Therapeutics' earnings report can be found in their filing with the SEC.
View SEC filing

Halozyme Therapeutics (NASDAQ:HALO) has a recorded annual revenue of $1.40 billion.

Halozyme Therapeutics (NASDAQ:HALO) has a recorded net income of $316.89 million. HALO has generated $3.93 earnings per share over the last four quarters.

Halozyme Therapeutics (NASDAQ:HALO) has a trailing price-to-earnings ratio of 24.55 and a forward price-to-earnings ratio of 9.85. The price/earnings-to-growth ratio is 0.38.

Halozyme Therapeutics' earnings are expected to grow from $8.34 per share to $9.80 per share in the next year, which is a 17.51% increase.


Earnings data for NASDAQ:HALO is sourced from Fiscal.ai, with the most recent quarter reported on 11/5/2026. New results are added as companies report their earnings.
From Our Partners